Bio Roundup: Trump’s Triumph, Election Fallout, CRISPR Arguments & More
Xconomy
NOVEMBER 11, 2016
—Oral arguments in the landmark patent fight over ownership of the gene editing technology CRISPR-Cas9 were set for Dec. Patent and Trademark Office. —Despite the patent fight, CRISPR work continues apace. —Despite the patent fight, CRISPR work continues apace. The Nitto drug is in a Phase 1b study.
Let's personalize your content